Pharmaceuticals, Biotechnology and Life Sciences
Denali Therapeutics, a neurodegenerative diseases specialist, on Tuesday brought to public positive results from its Phase 1 healthy volunteer study of DNL747, a brain penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1),
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the @Regeneron Pharmaceuticals and Sanofi made supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.
Denali Therapeutics will work with Sanofi on its multiple RIPK1 inhibitor molecules that could treat a range of neurological and systemic inflammatory diseases.
Sanofi reported €762m of net income in the second quarter 2018, after net sales of €8,176 million, down 5.7% on a…
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe…
Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the…
Sanofi and Ablynx have completed the acquisition, as Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx.
Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare…
Sanofi’s pivotal Phase 3 test of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents met its primary and key secondary…
Sanofi’s Head of Global Research and Development, Elias Zerhouni, will retire from the company after more than 9 years, in the…